
Opinion|Videos|December 5, 2025
Introductions
Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.
Advertisement
Episodes in this series
In this opening segment, the panelists introduce themselves and set the stage for the series, outlining the purpose of the discussion and the key CDK4/6 inhibitor data featured at ESMO 2025. Viewers are oriented to the trials that will anchor the conversation and the clinical questions the experts aim to explore throughout the program.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
2
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
3
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
4
Trump Executive Order Recommends Separating MMR Into 3 Shots
5


































































































